Cell Therapeutics Inc (NASDAQ:CTIC) Stock Rose By 3.70%


Dallas, Texas 11/21/2013 (Financialstrend) – In Wednesday’s trading session, Cell Therapeutics Inc (NASDAQ:CTIC) rose by 3.70%. The opening price of the shares was $1.93, which climbed to an intraday high of $1.98 and headed to close at $1.96. Around 3.55 million shares were exchanged on Wednesday while the average-volume of 3.42M shares were traded over a 30 day period. The 52-week low of Cell Therapeutics Inc (NASDAQ:CTIC) shares is $0.97 while the 52-week high is $2.17. The company has a market capitalization of $254.56 million.

About the company

Cell Therapeutics Inc (NASDAQ:CTIC) was formed on 4th September 1991. It is a bio-pharmaceutical company that focuses on acquiring, development & commercializing less-toxic methods of treating cancer. Cell Therapeutics Inc (NASDAQ:CTIC) is focusing its efforts on the treatments that effectively target blood-related cancers where unmet medical needs exist. Cell Therapeutics Inc (NASDAQ:CTIC) is mainly focused on the commercialization of PIXUVRI in the European Union. This is used to treat multiplies relapsed / refractory aggressive non-Hodgkin-lymphoma. The company is conducting a Phase-III clinical-trial of pacritinib for treating myelofibrosis. The drug PIXUVRI is a novel-aza-anthracenedione derivative and is structurally-related to anthracyclines & anthracenediones. However, it does not seem to be associated with the same-level of cardio-toxic effects.


Anthracyclines are potent classes of various anti-cancer agents that are used in 1st-line treatment of the aggressive diseases like NHL, leukemia &breast cancer. For all these diseases, anthracycline-containing-regimens can generally produce long-term cancer-remissions and cures. This toxicity many a times prevents the repeat use of anthracyclines in those patients who relapse post 1st-line anthracycline treatment. In addition to this, the cardiac-toxicity of anthracyclines also prevents their use as a mix with numerous other drugs that might also cause cardiac-toxicity. PIXUVRI is also being developed to improve the activity & safety in treating those cancers that usually initially treated with anthracycline family of the anti-cancer agents.

Subscribe to get your free report!

* indicates required
*Past performance is not a predictor of future results. All investing involves risk of loss and individual investments may vary. The examples provided may not be representative of typical results. Your capital is at risk when you invest – you can lose some or all of your money. Never risk more than you can afford to lose.By submitting your information you agree to the terms of our Privacy Policy • Cancel Newsletter Any Time.This is a FREE service from Finacials Trend. Signing up for our FREE daily e-letter also entitles you to receive this report. We will NOT share your email address with anyone.